Adial Pharmaceuticals Inc (ADIL)

$0.33 +0.01 (1.91%)
Market Cap 6.96M
Revenue (ttm) 0.00
Net Income (ttm) -13.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 358,500
Avg Vol 621,364
Day's Range N/A - N/A
Shares Out 21.83M
Stochastic %K 38%
Beta 1.32
Analysts Strong Sell
Price Target $2.17

Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and i...

Industry: Biotechnology
Sector: Healthcare
Phone: (804) 487-8196
Address:
4870 Sadler Road, Suite 300, Glen Allen, United States
Adamk88
Adamk88 Nov. 14 at 5:49 PM
$ADIL https://www.globenewswire.com/news-release/2025/11/14/3188326/26135/en/Adial-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
0 · Reply
David_M_
David_M_ Nov. 14 at 5:48 PM
$ADIL
0 · Reply
KING00777
KING00777 Nov. 14 at 3:05 PM
$ADIL Anything positive in 10Q?
0 · Reply
dogood
dogood Nov. 14 at 1:34 PM
$ADIL great quarter report
0 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Nov. 14 at 3:12 AM
$ADIL anyone know how much longer this stock has to fall out of compliance
2 · Reply
HOPE77711
HOPE77711 Nov. 13 at 9:21 PM
$ADIL Good results. It should fly now.
2 · Reply
Prazzclatt
Prazzclatt Nov. 13 at 8:45 PM
$ADIL curious what the next catalyst will be, only a matter of time before this gets back on track imo
0 · Reply
dln101
dln101 Nov. 13 at 5:50 PM
$ADIL maybe next penny to spike after $TNMG $NVVE 🤔💪🔥🚀
0 · Reply
KNOT_PANICAN
KNOT_PANICAN Nov. 13 at 2:10 PM
$ADIL
0 · Reply
topstockalerts
topstockalerts Nov. 12 at 9:31 PM
After Hours Top Gainers PT2 $WLDS $RVYL $IMMX $BRLS $ADIL
0 · Reply
Latest News on ADIL
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Oct 17, 2025, 9:00 AM EDT - 4 weeks ago

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Oct 9, 2025, 8:30 AM EDT - 5 weeks ago

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Sep 16, 2025, 8:00 AM EDT - 2 months ago

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Sep 3, 2025, 8:30 AM EDT - 2 months ago

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 8:30 AM EDT - 3 months ago

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Aug 6, 2025, 8:00 AM EDT - 3 months ago

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Jul 16, 2025, 8:30 AM EDT - 4 months ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Jul 9, 2025, 8:30 AM EDT - 4 months ago

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Jun 25, 2025, 8:30 AM EDT - 5 months ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 8:30 AM EDT - 6 months ago

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

May 13, 2025, 8:30 AM EDT - 6 months ago

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

May 2, 2025, 11:48 AM EDT - 7 months ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

May 1, 2025, 8:30 AM EDT - 7 months ago

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Mar 4, 2025, 8:30 AM EST - 9 months ago

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Feb 25, 2025, 9:00 AM EST - 9 months ago

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Feb 19, 2025, 9:00 AM EST - 9 months ago

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Feb 12, 2025, 9:00 AM EST - 9 months ago

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jan 29, 2025, 9:00 AM EST - 10 months ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Dec 3, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Nov 5, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Aug 7, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jul 23, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

May 29, 2024, 8:30 AM EDT - 1 year ago

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Apr 22, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Apr 10, 2024, 2:15 PM EDT - 1 year ago

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Apr 10, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Mar 1, 2024, 7:00 PM EST - 1 year ago

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Feb 28, 2024, 9:30 AM EST - 1 year ago

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Feb 15, 2024, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Feb 13, 2024, 9:15 AM EST - 1 year ago

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Jan 18, 2024, 8:30 AM EST - 1 year ago

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Dec 20, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Nov 29, 2023, 4:05 PM EST - 2 years ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 14, 2023, 5:02 PM EST - 2 years ago

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 24, 2023, 4:30 PM EDT - 2 years ago

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 20, 2023, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

Oct 19, 2023, 12:00 PM EDT - 2 years ago

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Oct 19, 2023, 10:30 AM EDT - 2 years ago

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

Oct 18, 2023, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Sep 28, 2023, 7:00 AM EDT - 2 years ago

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Adamk88
Adamk88 Nov. 14 at 5:49 PM
$ADIL https://www.globenewswire.com/news-release/2025/11/14/3188326/26135/en/Adial-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
0 · Reply
David_M_
David_M_ Nov. 14 at 5:48 PM
$ADIL
0 · Reply
KING00777
KING00777 Nov. 14 at 3:05 PM
$ADIL Anything positive in 10Q?
0 · Reply
dogood
dogood Nov. 14 at 1:34 PM
$ADIL great quarter report
0 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Nov. 14 at 3:12 AM
$ADIL anyone know how much longer this stock has to fall out of compliance
2 · Reply
HOPE77711
HOPE77711 Nov. 13 at 9:21 PM
$ADIL Good results. It should fly now.
2 · Reply
Prazzclatt
Prazzclatt Nov. 13 at 8:45 PM
$ADIL curious what the next catalyst will be, only a matter of time before this gets back on track imo
0 · Reply
dln101
dln101 Nov. 13 at 5:50 PM
$ADIL maybe next penny to spike after $TNMG $NVVE 🤔💪🔥🚀
0 · Reply
KNOT_PANICAN
KNOT_PANICAN Nov. 13 at 2:10 PM
$ADIL
0 · Reply
topstockalerts
topstockalerts Nov. 12 at 9:31 PM
After Hours Top Gainers PT2 $WLDS $RVYL $IMMX $BRLS $ADIL
0 · Reply
Mikemelga2024
Mikemelga2024 Nov. 12 at 8:22 PM
$ADIL Add more
0 · Reply
Hire1
Hire1 Nov. 12 at 4:28 PM
$ADIL upcoming week new catalyst
0 · Reply
Perfect_Thinking
Perfect_Thinking Nov. 12 at 2:22 PM
$ADIL something is brewing up lets hope a good line of fda final phase is comming soon.. holding tight...
0 · Reply
dogood
dogood Nov. 12 at 12:48 PM
$ADIL they have to publish one good news , if so we are set to $2
0 · Reply
Mikemelga2024
Mikemelga2024 Nov. 11 at 11:50 PM
$ADIL
1 · Reply
dogood
dogood Nov. 11 at 11:13 PM
$ADIL long waiting to see , run back to $3 , same for $BURU
0 · Reply
dogood
dogood Nov. 11 at 12:27 PM
$ADIL why the bid and ask are far?
0 · Reply
dln101
dln101 Nov. 10 at 7:40 PM
$ADIL itching to give a spike like $AZTR $HBIO did last week 🤔💪🔥🚀
0 · Reply
kedute
kedute Nov. 10 at 6:46 PM
$ADIL doubled my small position & opened second pint of Guinness.
0 · Reply
dogood
dogood Nov. 10 at 12:34 PM
$ADIL team of big guys are holding it at this level, not to go higher $1.5 as per analysts
1 · Reply
dogood
dogood Nov. 7 at 7:32 PM
$ADIL all are waiting , good pipeline and approvals
0 · Reply
dogood
dogood Nov. 7 at 3:05 PM
$ADIL not sure when can I see $1.5 run with large volume
1 · Reply